Business Context and Reporting Period
This Form 8-K is a current report filed by Rexahn Pharmaceuticals, Inc. (not Opus Genetics, Inc.) on January 15, 2014, regarding events occurring on January 14 and January 15, 2014. The filing details the entry into a material definitive agreement for a registered direct offering of securities.
Key Financial Metrics and Transaction Details
- Offering Size: $20 million in aggregate gross proceeds.
- Security Structure: Units consisting of one share of common stock and a five-year warrant to purchase 0.25 of a share.
- Offering Price: $1.05 per unit.
- Warrant Terms: Exercise price of $1.28 per share; warrants are exercisable for approximately 4.76 million shares.
- Shares Issued: Approximately 19.05 million shares of common stock.
- Placement Fees: Aggregate fee of 6% of gross proceeds paid to placement agents (Roth Capital Partners, LLC as lead; H.C. Wainwright & Co., LLC as co-agent).
- Expense Reimbursement: Up to $40,000 for out-of-pocket expenses incurred by the lead agent.
Material Changes and Transaction Status
The primary material change is the execution of a securities purchase agreement to raise capital. The filing does not provide comparative financial data (revenue, profit, cash flow, or debt levels) as this is a transactional report rather than a periodic financial statement. The offering is expected to close on or about January 21, 2014, subject to customary closing conditions.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on operational outlook, or specific risk factors beyond standard closing conditions. The document explicitly states that the representations and warranties in the agreements are not intended for investors to obtain factual information about the current state of affairs and directs investors to other SEC filings for such information.
Investor Verification Checklist
- Verify the closing of the $20 million offering on or about January 21, 2014.
- Confirm the final number of shares issued and the dilution impact on existing shareholders.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) and Engagement Letter (Exhibit 1.1) for specific covenants.
- Check subsequent filings for the actual cash proceeds received after deducting the 6% placement fee and expenses.
- Monitor the company's use of proceeds as disclosed in future periodic reports.